Why ketoanalogues matter: rethinking nutrition in pre-dialysis CKD

Executive summary

Pre-dialysis chronic kidney disease (CKD) management in India sits between two awkward facts. The first is epidemiological: pooled community CKD prevalence in India is now estimated at 13.24 % (95 % CI 10.52–16.22) and has risen from 11.12 % in 2011–2017 to 16.38 % in 2018–2023, with rural and male predominance.¹ The second is structural: the country has roughly one nephrologist per 100 000 CKD patients and a serious shortage of trained renal dietitians, while baseline habitual protein intake in many adult Indian patients is already near or below 0.65 g/kg/day even without prescription.²

In this environment, ketoanalogue (KAA) supplementation combined with a low-protein or very-low-protein diet (LPD / VLPD) is one of the few non-pharmacological interventions with randomised evidence for slowing CKD progression and delaying dialysis initiation. It is also one of the most contested. The KDOQI 2020 nutrition guideline endorses 0.55–0.60 g/kg/day protein, or 0.28–0.43 g/kg/day VLPD plus KAA, to reduce risk of ESKD and improve quality of life.³ The KDIGO 2024 CKD guideline is more conservative, suggesting 0.8 g/kg/day for most CKD G3–G5 not on KRT.⁴ The Indian Society of Nephrology cautions that VLPD in India must be reserved for “selected patients with slowly progressive CKD, preserved appetite, normal nutritional status, under close supervision.”⁵

This evidence brief synthesises the open-access literature behind those positions, examines positive (Garneata 2016, Wang 2023, Cochrane 2020) and negative (Bellizzi ERIKA 2022, MDRD long-term follow-up) signals honestly, and frames where Nuketo® (standard-strength tablet) and Nuketo-DS® (double-strength tablet, designed to reduce pill burden) fit in routine Indian nephrology practice.

The position taken in this paper is conservative and patient-selective: KAA + LPD/VLPD is appropriate for adherent, dietitian-supervised, metabolically stable pre-dialysis CKD G4–G5 patients with preserved nutritional status, slowly progressive disease and reasonable life expectancy — and is inappropriate for frail elderly patients with established protein-energy wasting, in whom the BiCARB/ERIKA-type pragmatic data show no benefit.

1. The clinical problem in India

India’s CKD epidemiology has three features that change the nutrition calculus relative to North American/European data:

1. Disease burden is large and rising. The Talukdar 2025 systematic review pooled 18 community studies (n ≈ 38 000 participants) and reported 13.24 % CKD prevalence overall, with the rural population at 15.34 % and the southern zone at 14.78 %.¹ The Singh SEEK study (2013) put earlier prevalence at 17.2 %.⁶ India is now estimated to carry roughly the world’s second-largest CKD burden in absolute numbers.
2. Baseline protein intake is already low. Adult Indian renal-clinic populations frequently have habitual protein intake of 0.6–0.7 g/kg/day even before any restriction, owing to predominantly cereal-based vegetarian or low-meat diets.² Unsupervised additional protein restriction in this setting risks crossing into protein-energy wasting (PEW), particularly in lower socioeconomic strata where caloric intake is also borderline.
3. Dietitian access is scarce. Trained renal dietitians are concentrated in tertiary urban centres. The Indian Chronic Kidney Disease (ICKD) cohort, which enrolled 4 056 patients across multiple Indian centres, documented a population that is two-thirds rural and median eGFR 40 at recruitment — patients who in most published trials would already qualify for VLPD candidacy but who in practice are unlikely to have continuous dietitian follow-up.⁷

Any honest discussion of nutritional therapy in Indian CKD has to start from these three facts, not from the European trial population on which most of the published evidence was generated.

2. What ketoanalogues actually do

KAAs are nitrogen-free analogues of the essential amino acids (EAA), supplied as calcium salts (calcium-ketovaline, calcium-ketoleucine, calcium-ketoisoleucine, calcium-ketophenylalanine, calcium-α-hydroxy-methionine, plus the directly supplied EAAs lysine, threonine, tryptophan, histidine, tyrosine).

The mechanism, well-summarised in the Koppe/Fouque Nutrients 2019 review, is straightforward:⁸

• The α-keto acid backbone is transaminated using endogenous nitrogen (predominantly from urea and ammonia pools) to regenerate the parent essential amino acid.
• This recycles waste nitrogen that the kidney would otherwise need to excrete, lowering urea generation rate and the protein-bound uremic toxin load.
• A reduced dietary protein intake combined with KAA supplementation therefore maintains nitrogen balance and lean body mass without requiring the kidney to clear the urea load of a normal-protein diet.
• The calcium salt formulation simultaneously provides a modest alkali buffer effect, contributing to metabolic acidosis correction, and through reduced phosphate intake and improved acidosis tends to lower intact PTH and serum phosphate.

Newer mechanistic work in Nutrients and MDPI Biomedicines has also documented favourable changes in the gut microbiome (relative increase in saccharolytic genera), reductions in protein-bound uremic toxins (indoxyl sulfate, p-cresyl sulfate), and improvements in endothelial function and protein carbamylation markers.⁹¹⁰¹¹

In practical terms: an Indian CKD G4 patient on 0.3 g/kg/day vegetarian protein plus appropriately dosed KAA supplementation gets the nitrogen-balance equivalent of a 0.55–0.60 g/kg/day mixed-protein diet, with substantially less urea generation and less acid load.

3. The pivotal positive evidence

3.1 Garneata 2016 — the strongest single RCT

The Garneata et al. JASN 2016 trial remains the most influential modern RCT of KAA-supplemented VLPD.¹² It enrolled 207 non-diabetic adults with eGFR < 30 and proteinuria < 1 g/g into a 15-month open-label intervention after a 3-month run-in:

• Intervention arm: vegetarian VLPD 0.3 g/kg/day + KAA 1 capsule per 5 kg body weight per day
• Comparator arm: conventional LPD 0.6 g/kg/day mixed protein
• Primary endpoint (composite): renal replacement therapy initiation or > 50 % eGFR decline

The result: the primary endpoint occurred in 13 % of the KAA + VLPD arm vs 42 % of the LPD arm (number needed to treat in the single digits over 15 months). Nutritional markers (serum albumin, BMI) were preserved in both arms.

The trial is rightly central to the case for KAA, but its limitations matter for Indian practice: it was single-centre (Bucharest), open-label, included only non-diabetic patients with modest proteinuria, and the 3-month run-in pre-selected adherent patients. The control diet (0.6 g/kg) is more permissive than the KDIGO 2024 default (0.8 g/kg), inflating the relative benefit somewhat.

3.2 Wang 2023 — large real-world cohort

A Taiwanese EMR cohort published in Scientific Reports analysed 38 005 pre-dialysis CKD patients with electronic-record-derived dietary intake and KAA prescription data.¹³ LPD + KAA was associated with significantly slower kidney progression than LPD alone, with a clear dose-response: benefit was greatest above 6 KAA tablets per day. This is the largest real-world dataset supporting the dose-response framing that justifies the existence of a double-strength formulation like Nuketo-DS for high-dose use cases.

The trade-off is the standard one for observational cohorts: residual confounding by indication (sicker patients may have been less likely to receive high-dose KAA) and EMR-derived intake validation issues. The Taiwanese diet profile, while not identical, is more comparable to Indian dietary patterns than the Bucharest cohort.

3.3 Cochrane 2020

The Hahn / Hodson / Fouque Cochrane review pooled 17 RCTs and quasi-RCTs in 2 996 non-diabetic adults with CKD.¹⁴ Key findings:

• VLPD (with or without KAA) probably reduces progression to ESKD in CKD 4–5 (moderate-certainty evidence).
• LPD 0.5–0.6 g/kg/day in CKD 3 makes little or no difference (low-certainty).
• No effect on all-cause mortality across pooled trials.
• Adverse-event and quality-of-life data are sparse — a real weakness of the evidence base.

This is the most defensible single citation for the existence of a benefit on ESKD progression in CKD 4–5.

3.4 Other supportive evidence

• Jiang 2018 meta-analysis (10 RCTs + 2 non-RCTs, n = 951): KAA significantly slowed eGFR decline (most pronounced at eGFR > 18), reduced serum phosphate and PTH, without any malnutrition signal vs control.¹⁵
• Li 2020 meta-analysis on long-term effects in advanced CKD on LPD: favourable trends on hard outcomes.¹⁶
• Wang 2022 meta-analysis specifically in diabetic kidney disease: positive renal outcomes signal in a population often excluded from earlier trials.¹⁷
• 2025 narrative review in PMC: balanced synthesis that frames KAA + LPD as appropriate in selected advanced-CKD patients.¹⁸

4. The honest counter-evidence

A credible white paper on KAA cannot ignore the negative data.

4.1 MDRD long-term follow-up

The Modification of Diet in Renal Disease (MDRD) trial (Klahr 1994) and its long-term observational follow-up (Menon 2009) is the largest historical RCT of LPD and VLPD + keto-amino-acid supplementation in CKD. The follow-up paper found that VLPD + keto-amino acids did not delay kidney failure during long-term observation and was associated with an increased mortality risk in the trial period.¹⁹

The MDRD follow-up is the most commonly cited single piece of evidence against routine VLPD + KAA. Its limitations are also well known: the keto-amino-acid mix used was not identical to modern KAA products, adherence to the very-low-protein arm was variable, and post-trial nutritional support was minimal. But the mortality signal cannot be dismissed and must be discussed candidly with patients.

4.2 ERIKA 2022 — pragmatic null trial

The Bellizzi et al. ERIKA pragmatic RCT, published in the American Journal of Clinical Nutrition in 2022, randomised advanced-CKD patients under regular nephrology care to KAA-supplemented VLPD vs standard LPD and reported no additional benefit of sVLPD over standard LPD on time to renal death or mortality in a real-life setting.²⁰

ERIKA matters because it is a “real life” trial — not a pre-selected adherent cohort with intensive dietitian support. Its null result is broadly consistent with what would be expected when adherence to 0.3 g/kg/day in routine practice falls short of trial-level execution. The accompanying editorial frames it as a sobering reality check for the Garneata-derived enthusiasm.²¹

4.3 What the divergence means in practice

The positive RCTs are intensively supervised; the negative real-world trials are not. The honest reading is that KAA + LPD/VLPD probably can slow CKD progression if implemented properly, but the implementation quality is a substantial moderator of the effect. The clinical implication is direct: patient selection and dietitian access are not optional — they are the rate-limiting step on real-world benefit.

5. The Indian-specific RAND/UCLA framing

A 2024 RAND/UCLA appropriateness consensus on KAA, calcium citrate and inulin in CKD provides the most clinically actionable framing for which patients should and should not be candidates.²² Distilled, the appropriate-candidate phenotype is:

• Pre-dialysis CKD G4–G5 (eGFR < 30, especially < 20)
• Slowly progressive trajectory (eGFR slope > –5 mL/min/1.73 m²/year)
• Preserved nutritional status (serum albumin ≥ 3.8 g/dL, no recent weight loss, hand-grip within normal for age)
• Adherent, dietitian-accessible patient
• No active major catabolic illness, no large protein-losing condition (proteinuria > 3 g/g)
• Reasonable life expectancy in which slowing dialysis initiation is a clinically meaningful goal

The inappropriate-candidate phenotype is essentially the inverse, and centrally includes: frail elderly with sarcopenia or established protein-energy wasting; patients with poor adherence history; patients with rapidly progressive disease where dialysis initiation is imminent regardless of intervention; and patients without access to dietary supervision.

This is the framing Vyapitus brings to Nuketo and Nuketo-DS prescribing communications. It maps closely to the Indian Society of Nephrology’s caution.⁵

6. Safety, pill burden and the case for Nuketo-DS

Two safety considerations dominate the practical conversation:

6.1 Calcium load

KAA preparations are calcium salts. A typical day’s prescription (1 tablet per 5 kg body weight) delivers ~50 mg of elemental calcium per tablet, i.e. roughly 500–700 mg/day of elemental calcium for a 60–70 kg adult. The safety review by Bellizzi and Cupisti (PMC 2018) concluded that serum calcium does not consistently rise on KAA, but cautioned that the calcium load is non-trivial and that patients with vascular calcification, on active vitamin D analogues, or with hypercalcemia at baseline warrant calcium monitoring.²³ The RAND/UCLA 2024 consensus supports the same monitoring posture.²²

In practice: a serum calcium and intact PTH check at baseline and every 3 months for the first year is reasonable, particularly in patients also on active vitamin D or calcium-based phosphate binders.

6.2 Pill burden and adherence

A 60 kg adult on standard-strength KAA at 1 tablet per 5 kg body weight requires 12 tablets per day, typically split across meals. The Hahn 2020 Cochrane review notes that adherence and quality-of-life data across the trial base are sparse, and the ERIKA pragmatic trial attributes its null result partly to real-world adherence limits.

Nuketo-DS (double-strength) is the formulation answer: a 60 kg adult takes 6 tablets per day instead of 12, halving the pill burden. The Wang 2023 EMR cohort signal that benefit was greatest above 6 tablets per day is directly relevant — without a double-strength option, achieving and sustaining therapeutic dosing in routine Indian practice is unrealistic for most patients.¹³

6.3 Drug-drug interactions

Calcium content can chelate tetracyclines, fluoroquinolones, levothyroxine and oral bisphosphonates. Separate dosing by at least 2 hours. This is a standard calcium-salt class effect, covered in the safety review.²³

6.4 What to monitor

A drop in serum albumin > 0.3 g/dL, weight loss > 5 % in 6 months, or hand-grip decline should trigger a dietetic re-evaluation and a discussion of stepping back from VLPD to LPD or discontinuing the intervention entirely.

7. Practical prescribing framework

7.1 Indication framing for Vyapitus material

Nuketo® and Nuketo-DS® are indicated as adjuncts to a low-protein or very-low-protein diet, prescribed and supervised by a qualified physician and renal dietitian, in metabolically stable pre-dialysis adult chronic kidney disease patients with the goal of preserving nitrogen balance and lean body mass while restricting protein intake.

This is the indication anchor. Off-label use in dialysis patients, in paediatrics, in pregnancy, or in acute kidney injury is not part of the Vyapitus positioning.

7.2 Dosing reference

Default dosing per published trial protocols and product literature:

• Standard: 1 tablet of standard-strength KAA per 5 kg body weight per day, split across meals
• Double-strength (Nuketo-DS): 1 tablet per 10 kg body weight per day, split across meals

Typical adult dosing ranges therefore:

The companion KAA calculator in apps/kaa-calculator/ operationalises this with explicit guardrails for low BMI, CKD stage, and elemental calcium load.

7.3 Dietary partner

The product is only as good as the diet it supports. The minimum standard is a written dietary prescription that specifies daily protein target (g/kg ideal body weight), energy target (≥ 30 kcal/kg/day for stable adults < 65 years, ≥ 30–35 kcal/kg/day for older), sodium, potassium, phosphate, and fluid targets, and includes patient-specific food substitutions for the Indian vegetarian/non-vegetarian context.

8. Where the field is heading

Three lines of work are worth tracking:

1. Targeted modulation of the gut–kidney axis. Mechanistic data on KAA reduction of indoxyl sulfate and p-cresyl sulfate, alongside microbiota shifts, raise the question of synergy with prebiotic/probiotic adjuncts.⁹¹⁰
2. Diabetic kidney disease. The Wang 2022 DKD meta-analysis is a positive signal in a population historically excluded; SGLT2-inhibitor co-treatment changes the trial baseline and re-opens the dosing question.¹⁷
3. Indian RCT generation. The closest mature Indian dataset is the ICKD cohort, but a prospective Indian RCT of KAA + LPD with hard endpoints remains conspicuously absent and is the single most valuable evidence-generation opportunity in the space.⁷

9. Bottom line for the prescribing clinician

• KAA + LPD/VLPD has moderate-certainty Cochrane-grade evidence for slowing progression to ESKD in CKD 4–5.¹⁴
• The Garneata RCT, Wang 2023 cohort and Jiang meta-analysis anchor the positive evidence base.¹²¹³¹⁵
• The MDRD long-term follow-up and ERIKA pragmatic trial are the strongest counterevidence and must be discussed candidly.¹⁹²⁰
• Implementation quality is the decisive moderator. Patient selection matters more than the molecule.
• In the Indian context — low baseline protein intake, sparse dietitian access — the inappropriate-use risk is real. The RAND/UCLA 2024 appropriateness frame is the recommended decision aid.²²
• Nuketo-DS exists because the Wang 2023 dose-response signal favoured > 6 tablets per day, and standard-strength dosing places that target beyond realistic adherence for most adult patients.¹³

KAA does not work for everyone. When prescribed to the right patient, supervised by the right team, it remains one of the few evidence-supported levers on the time to dialysis initiation in pre-dialysis CKD.

References

Disclaimers

This document is published by Vyapitus Specialities Private Limited for healthcare professionals only. See the project-level DISCLAIMER.md for the full medical, copyright, fair-use, and forward-looking-statement language. Doses, target ranges and indication framing reflect publicly available evidence and guidelines; the locally approved Summary of Product Characteristics for Nuketo® and Nuketo-DS® remains the authoritative prescribing reference. Vyapitus does not promote any of its brands outside the approved indication.